Alimentary Pharmacology & Therapeutics最新文献

{"title":"Letter: The Complexity of Deciphering Complex Mechanisms That Underpin Changing Trends in Complex Disease","authors":"Sasza Koczanowski, Jonathan P. Segal","doi":"10.1111/apt.70359","DOIUrl":"https://doi.org/10.1111/apt.70359","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"41 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144924066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Invasive Fungal Diseases in Patients With Alcohol-Related Hepatitis and Organ Failure.","authors":"Charlotte Mouliade, Lucia Parlati, Stylianos Tzedakis, Mathis Collier, Samir Bouam, Philippe Sogni, Fanny Lanternier, Alexandre Alanio, Vincent Mallet","doi":"10.1111/apt.70328","DOIUrl":"https://doi.org/10.1111/apt.70328","url":null,"abstract":"<p><strong>Background: </strong>The burden of invasive fungal diseases (IFDs) in patients with complicated alcoholic hepatitis (CAH)-defined by ≥ 2 hepatic (ascites, jaundice, liver failure, encephalopathy) or extrahepatic (coagulopathy, shock, kidney or respiratory failure) dysfunctions within 30 days-remains poorly characterised.</p><p><strong>Aims: </strong>To assess the burden of IFDs in CAH and compare it with bacterial pneumonia (BP).</p><p><strong>Methods: </strong>We conducted a retrospective nationwide cohort study of adult CAH patients in France (2012-2021). The primary exposure were IFDs. The primary outcome was 3-month mortality or liver transplantation. Associations were assessed with adjusted odds ratios (aORs) in complete-case and propensity score-matched cohorts. A 6-week landmark analysis and time-dependent Cox models were used to evaluate time-varying effects.</p><p><strong>Results: </strong>Among 11,434 CAH patients (median age 55 years; 72% male), 2.2% and 15% developed IFDs and BP, respectively. Three-month survival was 17.5% (95% CI: 13.0-23.0) in IFDs, 46.8% (44.3-49.3) in BP and 60.0% (59.4-61.4) in those without either (p < 0.001). IFDs occurred in 44.3% of patients with BP, and BP increased IFD risk (aOR 2.93, 95% CI: 2.23-3.84). In matched analyses, IFDs were associated with a fourfold increase in mortality (aOR 4.58, 95% CI: 3.02-7.20), while BP showed a lower association (aOR 1.23, 95% CI: 1.06-1.43). IFDs were strong time-dependent predictors of death.</p><p><strong>Conclusions: </strong>IFDs affected 1 in 50 CAH patients and carried a disproportionate mortality risk, compared with BP. These findings support the implementation of targeted screening and early antifungal strategies in CAH management, as for BP.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis","authors":"Lukas Burghart, Sonja Treiber, David Bauer, Emina Halilbasic, Benedikt S. Hofer, Mattias Mandorfer, Michael Gschwantler, Caroline Schwarz, Michael Trauner, Thomas Reiberger, Albert F. Stättermayer","doi":"10.1111/apt.70349","DOIUrl":"https://doi.org/10.1111/apt.70349","url":null,"abstract":"Background and AimsAutoimmune hepatitis (AIH) may progress to advanced chronic liver disease (ACLD) with clinically significant portal hypertension (CSPH). In this study, we evaluated the prevalence of different clinical CSPH features and their prognostic impact regarding decompensation, liver transplantation (LTX) and death in patients with AIH.MethodPatients with confirmed AIH diagnosis (sIAIHG‐Score ≥ 6) managed at the Vienna General Hospital between 2005 and 2023 were retrospectively analysed.ResultsAmong 271 included patients (76.4% female) with AIH, <jats:italic>n</jats:italic> = 60 (22.1%) presented clinical features of CSPH at diagnosis. During a median follow‐up of 7.2 (IQR 2.9–12.7) years, the proportion with CSPH features increased to <jats:italic>n</jats:italic> = 104 (38.4%). In a multivariable cox regression analysis, both compensated (aHR: 5.77, 95% CI: [1.47–22.71], <jats:italic>p</jats:italic> = 0.012) and decompensated features of CSPH (aHR: 15.73, 95% CI: [4.17–59.33], <jats:italic>p</jats:italic> &lt; 0.0001) were associated with an increased risk of LTX/death, whereas complete biochemical response and higher albumin levels were identified as protective factors. The BAVENO‐VII criteria for ruling‐out CSPH (liver stiffness &lt; 15 kPa and platelet count ≥ 150 G/L) identified AIH patients with a negligible 10Y cumulative incidence of hepatic decompensation (0.8%) and a favourable 10Y transplant‐free survival (97.8%). Overall, <jats:italic>n</jats:italic> = 16 (5.9%) patients died, with <jats:italic>n</jats:italic> = 10 deaths caused by CSPH‐related complications.ConclusionIn patients with AIH, clinical features of CSPH reflect the risk of future hepatic decompensation and mortality. Hence, regular screening for CSPH in AIH patients seems warranted to ensure timely initiation of adequate CSPH‐directed treatment.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"7 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.","authors":"Uma Mahadevan, Cynthia H Seow, Edward L Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto-Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard Gearry, Dana Duricova, Marla Dubinsky, Millie Long","doi":"10.1111/apt.70290","DOIUrl":"https://doi.org/10.1111/apt.70290","url":null,"abstract":"<p><strong>Background & aims: </strong>Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data.</p><p><strong>Methods: </strong>The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health.</p><p><strong>Results: </strong>The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements.</p><p><strong>Conclusions: </strong>Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144936990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study.","authors":"Raffaella Viganò, Alessandro Loglio, Clara Dibenedetto, Paola Carrai, Silvia Martini, Ilaria Lenci, Bianca Magro, Sara Conti, Paolo Angelo Cortesi, Chiara Mazzarelli, Chiara Becchetti, Giovanni Perricone, Monica Cucco, Marco Carbone, Donatella Cocchis, Elisa Farina, Luisa Pasulo, Mauro Viganò, Michele Sagasta, Elisabetta Degasperi, Davide Ghinolfi, Pietro Lampertico, Stefano Fagiuoli, Luca Saverio Belli","doi":"10.1111/apt.70348","DOIUrl":"https://doi.org/10.1111/apt.70348","url":null,"abstract":"<p><strong>Background & aims: </strong>Despite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside analogues (NAs) plus HBIG for long-term prophylaxis against hepatitis B virus (HBV) recurrence after liver transplant (LT). The aim of this study was to evaluate the safety of HBIG withdrawal in a cohort of LT recipients on long-term HBIG+NAs.</p><p><strong>Methods: </strong>All patients under third-generation NAs + HBIG and who adhered to the INSIGHT-B protocol were followed up after HBIG withdrawal, in a multicentre, prospective, Italian cohort study, to evaluate the risk of HBV reactivation. The probability of HBsAg reappearance after HBIG withdrawal, stratified by presence of HCC at LT, was estimated through Kaplan-Meier curves and Log-rank tests.</p><p><strong>Results: </strong>Between February 2021 and January 2024, 222 liver transplant (LT) recipients withdrew HBIG 11.6 (IQR 6.7-17.0) years after LT and were followed up for a median time of 24 months. After HBIG withdrawal, Hepatitis B surface antigen (HBsAg) reappearance was observed in 12 patients (5.4%) with a cumulative 1-, 2- and 3-year recurrence rate of 4.08%, 5.36% and 6.89% respectively. HBsAg serum levels remained very low over the entire period of observation (median 9 months, range 3-20), and in four cases fluctuated around the detectability threshold. In all cases, HBV-DNA persisted undetectable, liver function tests (LFTs) remained within the normal range, and neither HBV-related hepatitis nor HCC were observed. No baseline patients' features were found to be significantly associated with the likelihood of HBsAg reappearance after HBIG withdrawal, including the presence of HCC at transplantation.</p><p><strong>Conclusions: </strong>HBIG could be safely withdrawn in HBV mono-infected LT recipients on long-term combination HBIG plus third generation NAs.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemetric Assessment and Comparison of Regional Colonic Metabolic Activity in Ambulant Healthy Individuals Using pH and Gas‐Sensing Wireless Motility Capsules","authors":"Phoebe A. Thwaites, Chu K. Yao, Jasjot Maggo, Francis C. Parker, Emma P. Halmos, Rebecca E. Burgell, Jane G. Muir, Daniel So, Kourosh Kalantar‐Zadeh, Richard B. Gearry, Peter R. Gibson","doi":"10.1111/apt.70345","DOIUrl":"https://doi.org/10.1111/apt.70345","url":null,"abstract":"BackgroundIngestible wireless motility capsules enable locoregional quantification of luminal pH and concentrations of hydrogen and carbon dioxide in the human colon.AimTo evaluate these measures in the colon of healthy adults.MethodsGas‐sensing and pH‐sensing wireless motility capsules were ingested tandemly and repeatedly over time. Measurements were analysed and compared in proximal and distal segments of the colon.ResultsIn paired datasets from 37 participants, colonic pH rose from a median 6.3 (IQR 5.8–6.9) proximally to 7.0 (6.6–7.2) distally (<jats:italic>p</jats:italic> &lt; 0.001). Concentrations of carbon dioxide rose in nearly all participants from 12.7 (9.1–18.6) proximally to 18.8 (11.9–28.1) %.h/h distally (<jats:italic>p</jats:italic> &lt; 0.001) with a positive correlation between proximal and distal colon (<jats:italic>r</jats:italic> = 0.76; <jats:italic>p</jats:italic> &lt; 0.001). Hydrogen concentrations showed widely varied proximal‐to‐distal gradients with an increase in 69% of participants, but no correlation between proximal and distal colon measures. No significant correlations between colonic pH, hydrogen concentrations, and carbon dioxide concentrations were observed. Comparison of hydrogen and carbon dioxide concentrations between tandem gas‐sensing capsules by Bland–Altman analysis (<jats:italic>n</jats:italic> = 24) showed minimal (&lt; 1.2%) bias for both measures, and gas metrics on repeat ingestion were similar (<jats:italic>n</jats:italic> = 20). However, there was greater variance in the distal colon.ConclusionsBoth wireless motility capsules evaluate different yet complementary aspects of colonic fermentation. Carbon dioxide concentrations that most likely reflect overall microbial metabolic activity were consistently greater distally, while proximal‐to‐distal gradients in hydrogen concentrations varied, likely due to inter‐subject variations in dietary carbohydrate and/or methanogenesis. Luminal pH poorly reflects carbohydrate fermentation in the distal colon.Trial RegistrationACTRN12619001219178 and ACTRN12622000422729","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"23 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study","authors":"Pinelopi Arvaniti, Ignasi Olivas, Ana Pascual‐Dapena, Mar Riveiro‐Barciela, Paula Esteban, Anna Aguilar, Indhira Pérez‐Medrano, Diana Horta, Arancha Caballero Marcos, Magdalena Salcedo, Isabel Conde, Elena Gómez, Inmaculada Castelló, Jesús Santa Bárbara, Álvaro Díaz‐González, Maria del Barrio, Sara Lorente, Beatriz Mateos, Ana Arencibia, Miguel Jiménez, Paqui Cuenca, Vanesa Bernal‐Monterde, Eva‐Maria Fernández, Sergio Rodríguez‐Tajes, Anna Pocurull, Helena Hernández‐Évole, Xavier Forns, Raul J. Andrade, Maria‐Carlota Londoño","doi":"10.1111/apt.70353","DOIUrl":"https://doi.org/10.1111/apt.70353","url":null,"abstract":"Background and AimsAcute or chronic exposure to drugs or herbal and dietary supplements (HDS) can cause drug‐induced autoimmune‐like hepatitis (DI‐ALH), a self‐limiting condition resembling autoimmune hepatitis (AIH). We investigated the prevalence of drug exposure among AIH patients at diagnosis to recognise cases of DI‐ALH and discern features predicting AIH development.MethodsWe retrospectively included 705 patients diagnosed with AIH. DI‐ALH was defined using published criteria. The clinical, biochemical, serological, and histological data of DI‐ALH and AIH were analysed to identify predictors of the evolution of each phenotype.ResultsMost patients were female (<jats:italic>n</jats:italic> = 496, 70%), with a median age of 57 years and a median follow‐up of 55 months. A 59% (<jats:italic>n</jats:italic> = 417) reported exposure to drugs or HDS, and 8% (<jats:italic>n</jats:italic> = 58) fulfilled the criteria for DI‐ALH. Statins and HDS were the most common culprits. Patients with DI‐ALH more frequently had acute severe or fulminant hepatitis (22% vs. 12%, <jats:italic>p</jats:italic> = 0.013) and higher transaminase levels (ALT: 966 vs. 591, <jats:italic>p</jats:italic> = 0.001) at diagnosis. In total, 97% of the patients received immunosuppression. DI‐ALH patients had a faster biochemical response than i‐AIH patients (4 vs. 5, <jats:italic>p</jats:italic> = 0.031), while treatment withdrawal was attempted in only 29% (<jats:italic>n</jats:italic> = 17). Approximately 30% (<jats:italic>n</jats:italic> = 17) of DI‐ALH cases presented a flare during follow‐up. Neither clinical, histological, nor serological findings nor RUCAM and RECAM could predict a DI‐ALH flare.ConclusionsDI‐ALH is often under‐recognised in clinical practice, leading to unnecessary long‐term immunosuppression. A causal relationship between drugs and AIH, along with an attempt to withdraw treatment and long‐term follow‐up, is essential to prevent overtreatment‐associated risks.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"3 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Corticosteroid Responsive Acute Severe Ulcerative Colitis—Revisiting Maintenance Approaches in the Era of Advanced Therapies","authors":"Mukesh Kumar Ranjan,&nbsp;Sudheer Kumar Vuyyuru","doi":"10.1111/apt.70288","DOIUrl":"10.1111/apt.70288","url":null,"abstract":"&lt;p&gt;Acute severe ulcerative colitis (ASUC) is a severe form of ulcerative colitis (UC) flare that requires urgent and timely intervention. Approximately one-fourth of patients with UC experience ASUC during their lifetime [&lt;span&gt;1&lt;/span&gt;]. ASUC is characterised by frequent bloody bowel movements and systemic inflammatory features. If not adequately controlled, it can lead to toxic megacolon and colonic perforation, often necessitating emergency colectomy. Intravenous corticosteroids remain the first-line treatment, although only about two-thirds of patients respond [&lt;span&gt;2, 3&lt;/span&gt;]. For non-responders, medical rescue therapy with cyclosporin, infliximab, or off-label JAK inhibitors (JAKi) may induce response. The primary goal of medical therapy in ASUC is rapid induction of remission, followed by effective maintenance therapy. However, there is limited evidence to guide optimal maintenance therapy following successful induction with corticosteroids.&lt;/p&gt;&lt;p&gt;Singh et al. [&lt;span&gt;4&lt;/span&gt;] reported a retrospective propensity-matched analysis comparing the effectiveness and safety of azathioprine and tofacitinib as maintenance therapy in 115 adult patients with ASUC who responded to intravenous corticosteroids. The authors reported a significantly lower cumulative probability of event-free survival (defined as absence of rehospitalization, corticosteroid use, therapy escalation, or colectomy) at 1 year in the azathioprine than in the tofacitinib group (44.0% vs. 75.0%; &lt;i&gt;p&lt;/i&gt; = 0.01). Patients managed with azathioprine had higher rates of re-hospitalisation (15.4% vs. 0%; &lt;i&gt;p&lt;/i&gt; = 0.003) and treatment escalation (13.8% vs. 2.0%; &lt;i&gt;p&lt;/i&gt; = 0.02), and lower rates of symptomatic remission and combined symptomatic plus biomarker remission at 1 year (40.0% vs. 23.1%; &lt;i&gt;p&lt;/i&gt; = 0.05; 22.0% vs. 16.9%; &lt;i&gt;p&lt;/i&gt; = 0.49, respectively). Although colectomy rates were comparable between the tofacitinib and azathioprine groups, the overall incidence of colectomy remained very low. On multivariate analysis, prior exposure to immunomodulators was associated with reduced maintenance success. A sensitivity analysis excluding patients with prior azathioprine exposure yielded similar results. These findings are consistent with the randomised controlled ACTIVE trial, in which steroid-responsive patients were randomised to receive infliximab and azathioprine or azathioprine alone. The combination therapy group had significantly lower rates of treatment failure over 12 months' follow-up compared to the azathioprine monotherapy group (53.3% vs. 81.5%; &lt;i&gt;p&lt;/i&gt; = 0.03) [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;A single episode of ASUC substantially increases the risk of colectomy, with the risk rising further with subsequent episodes [&lt;span&gt;1&lt;/span&gt;]. Even in patients who initially respond to intravenous corticosteroids, the likelihood of relapse and eventual colectomy remains high. While steroid responders may have a lower colectomy risk than those who required medical rescue therapy d","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"62 7","pages":"754-755"},"PeriodicalIF":6.7,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70288","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma","authors":"Ashwini Arvind, Hiroaki Kanzaki, Fouzia Ahmed, Naoto Fujiwara, Yujin Hoshida, Amit G. Singal","doi":"10.1111/apt.70355","DOIUrl":"https://doi.org/10.1111/apt.70355","url":null,"abstract":"Patients with hepatocellular carcinoma (HCC) often experience recurrence after curative therapies, underscoring a need for risk stratification models. We validated 6 and 13‐metabolite signatures in patients who achieved complete response following surgical resection or local ablation. Of 78 patients, 32 (41.0%) died and 40 (51.3%) experienced recurrence, of whom 35 (87.5%) had early recurrence. In multivariable analysis, the 6‐metabolite signature was associated with early recurrence (aHR 2.8, 95% CI 1.1–7.5), and the 13‐metabolite signature was associated with overall recurrence (aHR 2.5, 95% CI 1.1–6.0). These data support the potential role of serum metabolites in post‐treatment risk stratification for HCC recurrence.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"24 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice","authors":"Pedro Ochoa‐Allemant, Marina Serper","doi":"10.1111/apt.70320","DOIUrl":"https://doi.org/10.1111/apt.70320","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"107 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}